Abstract #3815

MRS metabolomics screening of human lung cancer with blood serum collected prior to disease diagnosis

L Cheng¹, Tjada Schult¹, Mara Lauer¹, Yannick Berker², Marcella Cardoso¹, Lindsey Vandergrift¹, Piet Habbel³, Johannes Nowak⁴, Martin Aryee¹, Mari Mino-Kenudson¹, and David Christiani⁵

¹Mass General Hospital, Boston, MA, United States, ²German Cancer Research Center, Heidelberg, Germany, ³Charite Medical University, Berlin, Germany, ⁴Julius-Maximilians University, Wuerzburg, Germany, ⁵Harvard T.H. Chan School of Public Health, Boston, MA, United States

Lung cancer (LuCa), the leading cause of cancer deaths, are often diagnosed late due to the lack of screening. Low-dose spiral CT can detect small and early stage LuCa lesions, but cannot practically be used as an annual LuCa screening tool. Metabolomics detects global metabolite variations under physiology and pathology. Metabolomic profiles measured from blood may reveal LuCa at early stages as a screening tool to triage suspicious patients to CT tests. Blood sera obtained from LuCa patients prior to their diagnosis were studied with MRS to establish LuCa screening metabolomic profiles to discover LuCa earlier and reduce death rates.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.